Davis Polk advised Novo Nordisk on the deal while Goodwin Procter represented Forma Therapeutics. Novo Nordisk announced its approximately $1.1 billion acquisition of Forma Therapeutics. Under the...
Novo Nordisk’s $1.1 Billion Acquisition of Forma Therapeutics
EQRx’s Merger with CM Life Sciences III
Goodwin Procter advised EQRx on the deal while White & Case LLP advised CM Life Sciences III Inc. EQRx, Inc. announced its definitive merger agreement with CM...
Nimbus Therapeutics’ $105 Million Private Financing Round
Goodwin Procter LLP advised Nimbus Therapeutics on the deal. Nimbus Therapeutics announced the closing of a $105 million private financing round which was led by BVF Partners...
Tango Therapeutics’ $353 Million Merger with BCTG Acquisition Corp.
Goodwin Procter LLP advised Tango Therapeutics on the deal while Wilson Sonsini Goodrich & Rosati represented BCTG Acquisition Corp. Tango Therapeutics announced its definitive merger agreement with...




























